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Nanoparticles exhibited exceptional properties for drug delivery via 
different routes with excellent pharmacokinetics profiles using 
minimal dosages with almost no systemic side effects. The delivery 
of drug molecules for therapeutic applications usually faces problems 
of solubility and bioavailability that cubosomes can easily overcome. 
Cubosomes are cubic lipid-based nanoparticles with increased 
surface area, low viscosity and high heat stability. The preparation of 
cubosomes and drug encapsulation are still procedures requiring 
important improvements that have limit their use as drug delivery 
system. This work we developed a simple experimental procedure 
able to produce controlled-size cubosomes with different 
hydrodynamic size dependent of the phytantriol/ethanol 
(lipid/hydrotrope) ratio. Moreover, cubosomes were easily loaded 
with ciprofloxacin without structural changes. The results of this 
study will greatly impact on the applicability of cubosomes as drug 
delivery system.  
 
Introduction 
Nanotechnology is one of the most promising approaches 
assisting antimicrobial therapy design as it can provide novel 
vehicle systems to deliver antimicrobial agents. Nanoparticles 
exhibit exceptional properties for drug delivery via different 
routes with excellent pharmacokinetic profiles minimizing 
systemic side effects [1]. Generally, nanoparticles are entities 
that are usually less than 100 nm in diameter, in some cases 
between 100 and 500 nm, which are represented in the form of 
biodegradable or non-biodegradable drug carriers [1]. In 
clinical context, liposomes have been intensively investigated 
for drug delivery. Liposomes are spherical vesicles composed 
by bilayer membranes of amphiphilic lipids with an internal 
aqueous space and its relevance arises from their high 
biocompatibility, ability to incorporate both hydrophobic and 
hydrophilic drugs, safe drug delivery profiles and ease of 
preparation. However, liposomes still present limitations, such 
as storing stability, drug leakage and lack of size control and a 
limited loading capacity of lipophilic drugs, Hence, the use of 
liposomes for drug delivery is limited [2].   
Nanosized dispersions of liquid crystalline phases had attracted 
our attention because of their interesting approach of 
encapsulation and release of drugs [3,4]. This liquid crystal 
structures are composed by amphiphilic molecules that when 
mixed with right solvent have the ability to spontaneously self-
assemble leading to the formation of well-defined 
thermodynamically stable complexes, such as the cubosomes 
4. The colloidal dispersion of bicontinuous cubic liquid 
crystalline structures in water using suitable surfactant can 
result in cubosomes exhibiting 100 to 300 nm 5. Cubosomes 
are attractive drug delivery systems because they can 
incorporate a great variety of chemical compounds in their 
domains and exhibit larger surface area, lower viscosity and 
high heat stability 6,7. Although these unique 
physicochemical characteristics and the potential for controlled 
release through functionalization, the production of cubosomes 
has some challenges that need to be overcome, such as the 
presence of liposomes vesicles in the cubosomes dispersions 
and high energy input 4,6. 
Therefore, the main goal of this study was to strengthen the 
assumption that cubosomes will be the new trend in drug 
delivery system improving their preparation and drug 
encapsulation method. We aimed to develop and optimize the 
production of controlled-size cubosomes to further load them  
 
with ciprofloxacin (CIP), a fluoroquinolone antibiotic that is 
administrated to treat infections caused by gram-negative 
bacteria. Through an optimized controlled-size and an ease of 
preparation, cubosomes applicability as drug delivery systems 
would be greatly enlarged.  
 
Methods 
In this work, a bottom-up approach was used to form the 
cubosomes through the dispersion of a mixture comprising the 
liquid crystal forming lipid, the polymer and a hydrotrope in 
excess of water with minimal energy input 6. Based on phase 
diagram of the phytantriol (PT) – ethanol (ET) – water system 
described by Y. Chen et al. 8, different mixtures of 
phytantriol/ethanol (lipid/hydrotrope) were prepared as 
described in Table 1. The preparation of cubosomes also 
required a stabilizer in order to provide colloidal stability, 
prevent re-coalescence to bulk cubic phase and create stable 
dispersions 6,9. In this study, we used the block copolymer 
Pluronic F127 (or Poloxamer 407) dissolved in water. The 
initial solutions of phytantriol/ethanol described in Table 1 
were used to form cubosomes by solvent shifting. Briefly, 
phytantriol/ethanol solutions were added at once (solvent 
shifting) to different F127 solutions resulting in distinct PT: 
F127 ratios (Table 2). The resulting dispersions were stirred for 
2 min and kept at room temperature. To verify whether ethanol 
had influence on the structure and size of formed cubosomes, 
dispersions were led at room temperature overnight to promote 
ethanol evaporation. All the final dispersions prepared were 
labeled as, for instance, A1, the letter to identify the initial 
solution (Table 1) and the number to discern the final PT: F127 
ratio (Table 2). 
 
Table 1. Composition of the initial solutions used to form 
cubosomes. 
Sample 
Composition 
(phytantriol (w/w) 
Composition 
(ethanol (w/w) 
A 0.01 0.99 
B 
C 
0.05 
0.1 
0.95 
0.9 
 
The final dispersions were characterized in terms of particle 
size (hydrodynamic diameter) and polydispersity index (PDI) 
using a dynamic light scattering instrument (DLS) at angles of 
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90 º and 173 º. Measurements were performed at 25 ºC, during 
4 runs at 90 s each run. The results were analyzed using 
MATLAB software according to the functions described by 
Hassan et al. 10 with some optimizations. 
 
Table 2. Different final phytantriol/F127 ratio in the formed 
cubosomes. 
Sample series                                 PT: F127 ratio 
1 0.1 
2 
3 
4 
5 
0.5 
1 
5 
10 
 
To encapsulate CIP into cubosomes, the same method 
described above was used. CIP was dissolved in the mixture of 
phytantriol and ethanol and adding 1 M of NaOH until the 
mixture was completely dissolved and clean. At the end, the 
final dispersions were centrifuged at 2000 rpm for 5 min to 
remove the non-encapsulated CIP. The supernatants containing 
the cubosomes loaded with CIP were collected for DLS 
analysis.  
 
Results & Discussion 
Cubosomes were prepared using a bottom-up approach because 
it needs less energy input and produces cubosomes more 
efficiently, with smaller size, and long-term stability. 
Moreover, this approach is easily scale-up to commercial and 
industrial batches 6. Even though monoolein is the most 
common lipid used to prepare lipid nanoparticles, we used 
phytantriol due to its superior chemical stability, absence of the 
ester group and availability of commercial phytantriol with 
high purity 7,11.  
Before DLS measurements, the dispersions were first screened 
visually in order to discard the dispersions containing visible 
phase separation. For instance, dispersions from series 5 (A5 to 
C5) exhibited visible aggregates indicating that the resultant 
cubosomes were too large and not suitable for drug delivery 
proposes. Therefore, only transparent and clean dispersions 
were analyzed by DLS. 
DLS data demonstrated that our innovative experimental setup 
was able to produce cubosomes with diverse diameters in a 
controlled-size way. Using the dispersions A3, B2 and C1, we 
produced cubosomes with reduced size (hydrodynamic 
diameter), ranging from 150 to 270 nm, whereas using the 
dispersions B3 and C2 larger cubosomes (>300 nm) were 
obtained.  
 
Table 3. Hydrodynamic diameter and polydispersity index of 
the cubosomes dispersions. 
Sample name 
Hydrodynamic 
diameter 
(nm) 
Polydispersity 
index (PDI)  
A3 
A3* 
B2 
B2 + CIP 
B3 
B3 + CIP 
C1 
C2 
152 
148 
209 
265 
327 
344 
264 
354 
0.19 
0.17 
0.16 
0.28 
0.30 
0.52 
0.19 
0.25 
* Ethanol evaporation overnight. 
 
In terms of the polydispersity, all the dispersions showed to be 
monodisperse as PDI scores varied from 0.08 to 0.7 12. This 
result suggested that dispersions contained a unique and 
homogeneous population of cubosomes, indicating that 
controlled-size cubosomes were atttained. Moreover, these data 
reinforced the role of F127 in cubosomes stabilization without 
compromising the particle size. 
DLS results also showed that ethanol seemed not interfere in 
the structure of the cubosomes. The hydrodynamic diameter of 
cubosomes derived from A3 dispersion with and without 
ethanol evaporation was similar, as well as the PDI indicating 
both dispersion as monodisperse. 
CIP encapsulation into cubosomes demonstrated to be an easy 
procedure with satisfactory encapsulation efficacies. More 
importantly, cubosomes loaded with ciprofloxacin seemed not 
exhibit structural alterations. DLS data demonstrated that 
cubosomes derived from B2 and B3 dispersions with and 
without CIP had identical hydrodynamic diameter, approx. 286 
nm, and controlled-sized of cubosomes were still maintained as 
PDI score was below 0.7.  
In conclusion, our data revealed that controlled-size cubosomes 
with different range of diameters can be produced using a 
simple experimental workflow with minimal energy input. 
Ciprofloxacin encapsulation into cubosomes was easily 
performed and no structural alterations were detected. These 
findings will greatly impact on the applicability of cubosomes 
as drug delivery systems. 
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